Brand family
Glyxambi
Empagliflozin and Linagliptin · Boehringer Ingelheim Pharmaceuticals
United States
- Presentations
- 2
- Markets
- 1
Glyxambi is a brand of Empagliflozin and Linagliptin marketed by Boehringer Ingelheim Pharmaceuticals, with 2 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Empagliflozin and Linagliptin
- Brand owner
- Boehringer Ingelheim Pharmaceuticals
- Registered in
- United States
- Strengths and forms
- 10 mg/5 mg tablet, 25 mg/5 mg tablet
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Glyxambi 10 mg/5 mg tabletOral | Boehringer Ingelheim Pharmaceuticals | US FDA | Available on request |
| Glyxambi 25 mg/5 mg tabletOral | Boehringer Ingelheim Pharmaceuticals | US FDA | Available on request |
Brand names and trademarks belong to their owners and are used only to identify products.
Request Glyxambi
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.